Align Technology, Inc. vs Oscar Health Inc — how do they compare? Align Technology, Inc. trades at $173.38 (market cap $12.29B), while Oscar Health Inc trades at $29.54 (market cap $8.63B). The key difference: Align Technology, Inc. is the larger of the two by market cap, and Oscar Health Inc is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | OSCR | |
|---|---|---|
Market Cap | $12.29B | $8.63B |
Sector | Health | Health |
52-Week High | $197.51 | $32.18 |
52-Week Low | $124.88 | $10.85 |
Enterprise Value | $11.30B | $4.99B |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $174.63, down 0.8% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with record revenue and clear aligner volume. Fundamentals show solid profitability with a 68.05% gross margin and 9.99% net income margin, though revenue growth has moderated. Recent news highlights a patent win in China and strategic initiatives following activist investor engagement.
The outlook is mixed: analyst consensus is strongly bullish (73% buy ratings), but technicals and slowing revenue growth pose near-term risks. Investment opportunity lies in international expansion and digital dentistry platform growth, while risks include competitive pressures and execution of new strategic initiatives. The stock's valuation at 30x P/E requires sustained earnings growth to justify.
Oscar Health (OSCR) trades at $29.61, up 7.01% today, with technical indicators showing a bearish trend but oversold RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.1 per share, and raised its full-year outlook amid membership growth and cost control. Revenue surged 70% year-over-year to $4.9 billion for the first half of 2026, driving a net income turnaround to $551 million for the full year 2026.
The outlook is positive with robust revenue growth and profitability improvements, though risks include competitive pressures and reliance on Obamacare policies. Analysts have a consensus price target of $32.50, suggesting moderate upside, but hold ratings dominate due to execution risks.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →